These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 11835232)

  • 1. Cytogenetic abnormalities and clinical outcome in Wilms tumor: a study by the U.K. cancer cytogenetics group and the U.K. Children's Cancer Study Group.
    Bown N; Cotterill SJ; Roberts P; Griffiths M; Larkins S; Hibbert S; Middleton H; Kelsey A; Tritton D; Mitchell C
    Med Pediatr Oncol; 2002 Jan; 38(1):11-21. PubMed ID: 11835232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor: a report from the Children's Oncology Group.
    Gratias EJ; Jennings LJ; Anderson JR; Dome JS; Grundy P; Perlman EJ
    Cancer; 2013 Nov; 119(21):3887-94. PubMed ID: 23983061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gain of 1q is a marker of poor prognosis in Wilms' tumors.
    Segers H; van den Heuvel-Eibrink MM; Williams RD; van Tinteren H; Vujanic G; Pieters R; Pritchard-Jones K; Bown N;
    Genes Chromosomes Cancer; 2013 Nov; 52(11):1065-74. PubMed ID: 24038759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group.
    Gratias EJ; Dome JS; Jennings LJ; Chi YY; Tian J; Anderson J; Grundy P; Mullen EA; Geller JI; Fernandez CV; Perlman EJ
    J Clin Oncol; 2016 Sep; 34(26):3189-94. PubMed ID: 27400937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.
    Grundy PE; Breslow NE; Li S; Perlman E; Beckwith JB; Ritchey ML; Shamberger RC; Haase GM; D'Angio GJ; Donaldson M; Coppes MJ; Malogolowkin M; Shearer P; Thomas PR; Macklis R; Tomlinson G; Huff V; Green DM;
    J Clin Oncol; 2005 Oct; 23(29):7312-21. PubMed ID: 16129848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Correlation of 1p/16q loss of heterozygosity and 1p gain with clinicopathological characteristics and prognosis in Wilms tumor].
    Jia C; Yao XF; Zhang M; Guan XX; Wang JW; Song HC; He LJ
    Zhonghua Bing Li Xue Za Zhi; 2024 Mar; 53(3):257-263. PubMed ID: 38433053
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor: A Report From Children's Oncology Group AREN0532.
    Fernandez CV; Perlman EJ; Mullen EA; Chi YY; Hamilton TE; Gow KW; Ferrer FA; Barnhart DC; Ehrlich PF; Khanna G; Kalapurakal JA; Bocking T; Huff V; Tian J; Geller JI; Grundy PE; Anderson JR; Dome JS; Shamberger RC
    Ann Surg; 2017 Apr; 265(4):835-840. PubMed ID: 27811504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532.
    Fernandez CV; Mullen EA; Chi YY; Ehrlich PF; Perlman EJ; Kalapurakal JA; Khanna G; Paulino AC; Hamilton TE; Gow KW; Tochner Z; Hoffer FA; Withycombe JS; Shamberger RC; Kim Y; Geller JI; Anderson JR; Grundy PE; Dome JS
    J Clin Oncol; 2018 Jan; 36(3):254-261. PubMed ID: 29211618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: a Children's Cancer and Leukaemia Group (CCLG) Study.
    Messahel B; Williams R; Ridolfi A; A'hern R; Warren W; Tinworth L; Hobson R; Al-Saadi R; Whyman G; Brundler MA; Kelsey A; Sebire N; Jones C; Vujanic G; Pritchard-Jones K;
    Eur J Cancer; 2009 Mar; 45(5):819-26. PubMed ID: 19231157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profiling Loss of Heterozygosity Patterns in a Cohort of Favorable Histology Nephroblastoma Egyptian Patients: What is Consistent With the Rest of the World.
    Fawzy M; Bahanassy A; Samir A; Hafez H
    Pediatr Hematol Oncol; 2015; 32(8):548-56. PubMed ID: 26390800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study.
    Chagtai T; Zill C; Dainese L; Wegert J; Savola S; Popov S; Mifsud W; Vujanić G; Sebire N; Le Bouc Y; Ambros PF; Kager L; O'Sullivan MJ; Blaise A; Bergeron C; Mengelbier LH; Gisselsson D; Kool M; Tytgat GA; van den Heuvel-Eibrink MM; Graf N; van Tinteren H; Coulomb A; Gessler M; Williams RD; Pritchard-Jones K
    J Clin Oncol; 2016 Sep; 34(26):3195-203. PubMed ID: 27432915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytogenetic findings and clinical course in a consecutive series of Wilms tumors.
    Kullendorff CM; Soller M; Wiebe T; Mertens F
    Cancer Genet Cytogenet; 2003 Jan; 140(1):82-7. PubMed ID: 12550766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 17q gain in neuroblastoma predicts adverse clinical outcome. U.K. Cancer Cytogenetics Group and the U.K. Children's Cancer Study Group.
    Bown N; Lastowska M; Cotterill S; O'Neill S; Ellershaw C; Roberts P; Lewis I; Pearson AD;
    Med Pediatr Oncol; 2001 Jan; 36(1):14-9. PubMed ID: 11464868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome.
    Grundy PE; Telzerow PE; Breslow N; Moksness J; Huff V; Paterson MC
    Cancer Res; 1994 May; 54(9):2331-3. PubMed ID: 8162576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of Heterozygosity at Chromosome 16q Is a Negative Prognostic Factor in Korean Pediatric Patients with Favorable Histology Wilms Tumor: A Report of the Korean Pediatric Hematology Oncology Group (K-PHOG).
    Park JE; Noh OK; Lee Y; Choi HS; Han JW; Hahn SM; Lyu CJ; Lee JW; Yoo KH; Koo HH; Jeong SY; Sung KW
    Cancer Res Treat; 2020 Apr; 52(2):438-445. PubMed ID: 31505910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromosomal anomalies at 1q, 3, 16q, and mutations of SIX1 and DROSHA genes underlie Wilms tumor recurrences.
    Spreafico F; Ciceri S; Gamba B; Torri F; Terenziani M; Collini P; Macciardi F; Radice P; Perotti D
    Oncotarget; 2016 Feb; 7(8):8908-15. PubMed ID: 26802027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined Genetic and Chromosomal Characterization of Wilms Tumors Identifies Chromosome 12 Gain as a Potential New Marker Predicting a Favorable Outcome.
    Haruta M; Arai Y; Okita H; Tanaka Y; Takimoto T; Sugino RP; Yamada Y; Kamijo T; Oue T; Fukuzawa M; Koshinaga T; Kaneko Y
    Neoplasia; 2019 Jan; 21(1):117-131. PubMed ID: 30530054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromosome abnormalities in tumor cells from patients with sporadic Wilms' tumor.
    Kondo K; Chilcote RR; Maurer HS; Rowley JD
    Cancer Res; 1984 Nov; 44(11):5376-81. PubMed ID: 6091875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 16q heterozygosity loss in Wilms' tumour in children and its clinical importance.
    Skotnicka-Klonowicz G; Rieske P; Bartkowiak J; Szymik-Kantorowicz S; Daszkiewicz P; Debiec-Rychter M
    Eur J Surg Oncol; 2000 Feb; 26(1):61-6. PubMed ID: 10718182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of chromosome abnormalities with histological and clinical features in Wilms' and other childhood renal tumors.
    Kaneko Y; Homma C; Maseki N; Sakurai M; Hata J
    Cancer Res; 1991 Nov; 51(21):5937-42. PubMed ID: 1657374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.